



PRESS RELEASE

Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference

Lund, Sweden, January 3, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the JP Morgan 31st Annual Healthcare Conference held January 6-10, 2013 in San Francisco, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

The presentation will include the **laquinimod** MS project, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the Phase III prostate cancer project **TASQ** in co-development with Ipsen, as well as **ANYARA**, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project **57-57** and the pre-clinical **ISI** project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to – www.activebiotech.com.

The presentation will take place on **January 10**, at **8:00 am PST (Pacific Standard Time) / 17.00 Central European Time**.

***Active Biotech AB** (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. An additional project in clinical development is the orally administered compound 57-57 for Systemic Sclerosis. Please visit www.activebiotech.com for more information.*

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 10:00 a.m. CET on January 3, 2013.

Contacts:

Active Biotech AB

Hans Kolam, CFO

P.O. Box 724, SE-220 07 Lund, Sweden

Tel: +46 (0)46-19 20 00

Fax: +46 (0)46-19 11 00